Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Antibody-Drug Conjugates (ADCs)
    (2)
  • EGFR
    (2)
Filter
Search Result
Results for "

depatuxizumab

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    4
    TargetMol | Inhibitors_Agonists
  • Inhibitory Antibodies
    4
    TargetMol | Inhibitory_Antibodies
Depatuxizumab
ABT-806, ABT806
T783261471999-69-5
Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN).
  • $415
In Stock
Size
QTY
Depatuxizumab MMAE
T82582
Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising the anti-EGFR monoclonal antibody depatuxizumab linked to the cytotoxic agent monomethyl auristatin E (MMAE). This ADC effectively suppresses the growth of xenograft models harboring both mutant EGFRvIII and wild-type EGFR [1].
  • Inquiry Price
Size
QTY
Depatuxizumab mafodotin
ABT-414
T9901A-0271585973-65-4
Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].
  • $978
6-8 weeks
Size
QTY
Depatuxizumab MMAF
T9901A-197
Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.
  • Inquiry Price
Size
QTY